4 research outputs found
A gyermekkori Ewing szarkómával szerzett magyarországi tapasztalataink
Magyarországon évente kb. 7-9 új Ewing szarkómás gyermeket diagnosztizálunk. Jelen munkánk célja az volt, hogy az Országos Gyermektumor Regiszter adatait felhasználva
megvizsgáljuk a magyarországi Ewing szarkómás gyermekek
prezentáciĂłs tĂĽneteit, a klinikai paramĂ©tereket, a prognosztikai faktorokat, a terápiás Ă©s a tĂşlĂ©lĂ©si eredmĂ©nyeket 1992 Ă©s 2002 közötti 11 Ă©ves periĂłdusban. A fenti idĹ‘szakban 88 Ăşj beteg kerĂĽlt diagnosztizálásra, a fiĂş – leány arány 1,05 : 1 volt, az átlagĂ©letkor 11 Ă©v 7 hĂłnapnak bizonyult. A kĂ©t leggyakoribb prezentáciĂłs tĂĽnet a lokális fájdalom Ă©s duzzanat voltak. 38 betegĂĽnkben hosszĂş csöves csontra lokalizálĂłdott a megbetegedĂ©s, 29 gyermekben a Ewing szarkĂłma a csĂpĹ‘ tájĂ©krĂłl indult ki Ă©s 21 esetben valamely egyĂ©b testtájĂ©krĂłl. A betegeink közel egyharmadánál
(29/88) már a diagnĂłzis felállĂtásakor áttĂ©tek voltak
kimutathatóak. A fent nevezett időszakban három kemoterápiás
protokollt alkalmaztunk Magyarországon: a CWS, az
EICESS/CESS Ă©s 1999. decembere Ăłta az Euro-EWING 99
protokollt. A 88 beteg 37,5%-nál (33/88) Ă©szleltĂĽnk recidĂvát átlagosan 22,4 hĂłnappal a primer diagnĂłzis felállĂtása után. A 88 betegbĹ‘l 45 jelenleg is Ă©l, az átlag követĂ©si idĹ‘ 28,6 hĂłnap. Az összes beteg 5-Ă©ves kumulatĂv tĂşlĂ©lĂ©si valĂłszĂnűsĂ©ge 48,06±5,9%, a 10 Ă©ves 42,91±6,3%. A metasztázissal rendelkezĹ‘ betegek 5 Ă©s 8 Ă©ves tĂşlĂ©lĂ©se 19,91±9,4%, a metasztázis nĂ©lkĂĽliek 5 Ă©ves tĂşlĂ©lĂ©se 60,23±6,9%, mĂg a 10 Ă©ves 52,82±7,8%. A hazai eredmĂ©nyek megközelĂtik a nemzetközi adatokat, azonban törekednĂĽnk kell a diagnĂłzis korai felállĂtására Ă©s ezáltal a kimondottan rossz prognĂłzisĂş primer metasztatikus esetek számának csökkentĂ©sĂ©re.
The number of newly diagnosed children in a year with Ewing’s sarcoma is 7-9 in Hungary. The aim of our study
was to evaluate the presenting symptoms, clinical features,
prognostic risk factors and treatment results of children’s
Ewing’s sarcoma in Hungary using data from the National
Childhood Cancer Registry in a 11 years-long period between
1992 and 2002. In this period, 88 new patients were diagnosed, the male-female ratio was 1,05:1 and the mean age was 11 years 7 months. The two most common presenting symptoms were local pain and swallowing. Tumor was located in the pelvis area in 29 patients, in the extremities in 38 and other sites in 21 cases. Almost one third of our patients (29/88) had metastasis at the time of the diagnosis. In this time period, three different protocols were used for treatment: CWS, EICESS/CESS and since December 1999 Euro-EWING 99. 37,5% of our patients (33/88) had relapse with a mean of 22,4 months after the diagnosis. 45 children are still alive, the median follow-up time is 28,6 months. The overall survival (OS) of all patients (n=88) was 48,06±5,9% at 5 years and 42,91±6,3% at 10 years. Patients with metastasis had OS 19,91±9,4% at 5 and at 8 years. The 5-year OS of children without metastasis was 60,23±6,9%, and 52,82±7,8% at 10 years. The Hungarian data are similar to international results, but we have to try to decrease the number of the primary metastatic cases with early diagnosis
A Ewing-sarcomás betegek tünetmentes túlélési esélyeinek értékelése a Gyermekonkológiai Szekció eredményei alapján
A Magyar GyermekonkolĂłgiai Munkacsoport TumorregiszterĂ©ben 12 Ă©v során rögzĂtett 65 Ewing-sarcomás beteg adatait – prognosztikai szempontok szerint – elemeztĂĽk. CĂ©lunk a tĂşlĂ©lĂ©s vizsgálata volt. Ahol a rendelkezĂ©sĂĽnkre állĂł adatszám megengedte, következtetĂ©seinket statisztikai vizsgálatokkal is megerĹ‘sĂtettĂĽk. EredmĂ©nyek: Anyagunkban a panaszok megjelenĂ©sĂ©tĹ‘l a diagnĂłzis felállĂtásáig eltelt idĹ‘tartam szĂ©lsĹ‘Ă©rtĂ©kei: 2–16 hĂłnap. A tĂĽnetmentes tĂşlĂ©lĂ©s a metasztázissal nem rendelkezĹ‘knĂ©l Kaplan–Meier mĂłdszerĂ©vel 0,39, mĂg a pulmonalis vagy más (primer) áttĂ©tekkel
diagnosztizált betegeknél 0,24. Következtetések: Az eredmények az irodalmi túlélési adatok határértékei alatt maradnak, bár a különbség nem szignifikáns. A rosszabb eredmények döntő oka a későn felismert, metasztázissal diagnózisra került betegek viszonylagosan magas aránya.
Correlation between different prognostic factors and the overall survival of Ewing’s sarcoma patients has been investigted. In this study data have been selected from
the databank of Hungarian Pediatric Oncologist Section (1988-1999) (n=65). Whenever it was possible statistical analysis has been performed. Results: In our patients time interval from the primary symptoms to the diagnosis was 2-16
months. The average event-free survival in patients suffering from Ewing’s sarcoma without metastasis is 0.39. Meanwhile, this value in patients with pulmonary or other metatasis is 0.24 (Kaplan-Meier analysis). Conclusion: Our results show a moderate difference between the Hungarian and the international event-free survival. Late detection is one of the answers of this discrepancy
Fermented Wheat Germ Extract Reduces Chemotherapy-Induced Febrile Neutropenia in Pediatric Cancer Patients
Purpose: An open-label, matched-pair (by diagnosis, stage of disease, age, and gender) pilot clinical trial was conducted to test whether the combined administration of the medical nutriment MSC (Avemar) with cytotoxic drugs and the continued administration of MSC on its own help to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers compared with the same treatments without MSC.
Methods: Between December 1998 and May 2002, 22 patients (11 pairs) were enrolled in this study. At baseline, the staging of the tumors was the same in each pair (mostly pTNM T2N0M0), with the exception of two cases in which patients in the MSC group had worse prognoses (metastasis at baseline). There were no significant differences in the average age of the patients, the length of treatment time (MSC) or follow-up, the number of patients with central venous catheters, the number of chemotherapy cycles, the frequency of preventive counterneutropenic interventions, or the type and dosage of antibiotic and antipyretic therapy used in the two groups.
Results: During the treatment (follow-up) period.. there was no progression of the malignant disease, whereas at end-point the number and frequency of febrile neutropenic events significantly differed between the two groups: 30 febrile neutropenic episodes (24.8%) in the MSC group versus 46 (43.4%) in the control group (Wilcoxon signed rank test, P < 0.05).
Conclusions: The continuous supplementation of anticancer therapies with the medical nutriment MSC helps to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers